Published On: Wed, Oct 19th, 2016

Broker Changes For Histogenics Corporation (HSGX)


Recently stock market analysts have updated their consensus ratings on shares of Histogenics Corporation (HSGX).

Most recent broker ratings

09/19/2016 – Histogenics Corporation had its “buy” rating reiterated by analysts at Needham & Company. They now have a USD 8 price target on the stock.

09/07/2016 – Histogenics Corporation had its “market perform” rating reiterated by analysts at William Blair.

08/12/2016 – Histogenics Corporation was upgraded to “buy” by analysts at BTIG Research. They now have a USD 3.5 price target on the stock.

11/13/2015 – Histogenics Corporation had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 12.5 price target on the stock.

11/13/2015 – Histogenics Corporation had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 8 price target on the stock.

05/12/2015 – Histogenics Corporation was upgraded to “hold” by analysts at Zacks.

Histogenics Corporation has a 50 day moving average of 3.19 and a 200 day moving average of 2.38. The stock’s market capitalization is 37.69M, it has a 52-week low of 1.39 and a 52-week high of 4.97.

The share price of the company (HSGX) was up +2.90% during the last trading session, with a high of 2.89 and the volume of Histogenics Corporation shares traded was 32098.

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient’s own cartilage cells through a series of tissue engineering processes. The patient’s cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company’s Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.